Brian Corrigan

EVP, Drug & Biological Products


Brian Corrigan joined Greenleaf in August 2014, following more than a decade of professional experience in the biopharmaceutical industry. Brian uses his in-depth understanding of the U.S. healthcare system and the Food and Drug Administration (FDA) regulatory process to provide strategic and technical guidance to Greenleaf clients.

At Greenleaf, Brian has advised numerous clients in the drug and biologics space on interpreting FDA clinical expectations, navigating regulatory hurdles, and executing formal meetings with the FDA, while providing strategic support through the application review process toward product approval.

Brian also leads Greenleaf’s Advisory Services practice area, working with life science investors to evaluate potential issues and regulatory risks during the due diligence stage of transactions.

Before joining Greenleaf, Brian was a key member of the Government Affairs and Public Policy team at Vertex Pharmaceuticals. Brian led the development of Vertex’s regulatory policy strategies and worked closely with the company’s leadership to incorporate these strategies into business planning and clinical development initiatives. Brian also represented the company on industry trade association committees.

Brian joined Vertex Pharmaceuticals from Astellas Pharma U.S., where he worked on federal policy and governmental affairs issues.

Brian graduated magna cum laude from the George Mason University School of Law. He received his B.A. from Boston College, where he graduated magna cum laude and Phi Beta Kappa.

Ready for regulatory clarity? Contact us.